Survodutide Tracker
Track the GLP-1/Glucagon Dual Agonist in Phase 3
Survodutide (BI 456906) by Boehringer Ingelheim & Zealand Pharma showed up to 18.7% weight loss in Phase 2. Track weekly injections, weight, and liver health markers with Shotlee during Phase 3 trials.
What is Survodutide?
Survodutide (BI 456906) is a once-weekly subcutaneous peptide that activates both GLP-1 and glucagon receptors. It was developed through a collaboration between Boehringer Ingelheim and Zealand Pharma. Like pemvidutide, the glucagon component is intended to complement GLP-1's appetite suppression with additional energy expenditure benefits.
The Phase 2 LIGHT-UP trial in non-diabetic adults with obesity showed dose-dependent weight loss from 6.8% (0.6mg) up to 18.7% (4.8mg) over 46 weeks. Survodutide is also in Phase 2/3 trials for MASH (metabolic dysfunction-associated steatohepatitis), where GLP-1 drugs like Wegovy recently received FDA approval.
Phase 3 obesity trials are ongoing, with potential FDA approval as early as 2027. Survodutide positions itself as a strong competitor in the next wave of obesity drugs alongside CagriSema, MariTide, and pemvidutide.
FAQ
What is survodutide?
A weekly GLP-1/glucagon dual agonist from Boehringer Ingelheim & Zealand Pharma in Phase 3. Phase 2 showed up to 18.7% weight loss. Also being studied for MASH liver disease.
How does it compare to Mounjaro?
Phase 2 results show survodutide at 18.7% vs Mounjaro's ~20%. Very competitive. The glucagon mechanism may offer advantages for liver health and energy expenditure.
Can I track it on Shotlee?
Yes — log weekly injections with dose (up to 4.8mg), track weight, and log liver function markers. Perfect for Phase 3 trial participants.